Call Start: 16:30 January 1, 0000 5:06 PM ET

Ambrx Biopharma Inc. (NASDAQ:AMAM)

Q4 2021 Earnings Conference Call

April 26, 2022, 4:30 PM ET

Company Participants

Feng Tian – Chief Executive Officer

Sonja Nelson – Chief Financial Officer

Laurence Watts – Managing Director, Gilmartin Group

Conference Call Participants

Corinne Jenkins – Goldman Sachs

Tazeen Ahmad – Bank of America

Phil Nadeau – Cowen & Co.

Joel Beatty – Baird

Operator

Welcome to the Ambrx Second Half and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are on listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would like the limit of one question and one follow-up question per person. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, April 26, 2022. I would now like to turn the conference over to Laurence Watts, Managing Director at Gilmartin Group. Please go ahead.

Laurence Watts

Thank you, Jason. Joining us on the call today from Ambrx are Chief Executive Officer, Feng Tian, and Chief Financial Officer, Sonja Nelson. During this conference call, management will make forward-looking statements that are subject to risks and uncertainties related to the future events and or financial performance of the company. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties such as but not limited to those discussed in the Risk Factors section of our annual report on Form 20-F for the year ended December 31st, 2021 on file with the SEC. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result. With that, I will turn the call over to Feng Tian, Chief Executive Officer of Ambrx. Tian?

Feng Tian

Thank you. Laurence. Good afternoon, everyone. And thank you all for joining our second half on the full-year 2021 Financial Result Conference Call. I would like to start today's call by thanking the entire Ambrx, our partner in China, NovoCodex. And the physicians and the patients who have participated in our ongoing clinical trials. Without the collective efforts of those groups, the growth that we have experienced throughout the year would not be possible. Cumbersome made great strides in 2021 demonstrated through the expansion of its executive team, as well as a progression of its clinical developed pipeline. Despite ongoing challenges of COVID-19. On this quarter by the recent lockdowns, which are high. We continuing to see positive trends in enrollment in our trials. Before I talk about recent events and the future of Ambrx, I would like to review key milestones achieved in 2021.